Skip to Main content Skip to Navigation
Journal articles

Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis.

Philippe Manceau 1, * Clotilde Latarche 2 Sophie Pittion 1 Gilles Edan 3, 4, 5 Jérôme de Sèze 6 Catherine Massart 4, 7 Marc Debouverie 8, 1, 2
* Corresponding author
3 VisAGeS - Vision, Action et Gestion d'informations en Santé
INSERM - Institut National de la Santé et de la Recherche Médicale : U746, Inria Rennes – Bretagne Atlantique , IRISA-D5 - SIGNAUX ET IMAGES NUMÉRIQUES, ROBOTIQUE
8 Ecole de Santé Publique [Nancy]
Faculté de Médecine [Nancy]
Abstract : BackgroundThe clinical impact of neutralizing antibodies against interferon-beta (NAb) is controversial. Their presence can lead to a decrease in interferon-beta (IFNß) efficacy. Fatigue reported in patients with multiple sclerosis (MS) may be associated with an unfavorable clinical course. We conducted a prospective multicentre study to assess the association between response to IFNß, NAb and fatigue.MethodsPatients with relapsing-remitting MS on IFNß treatment were included. During the second year of treatment, the patients were analyzed for NAb status and non-response criteria to IFNß (number of relapses ¿1 during the follow-up period, increase in the Expanded Disability Status Scale ¿0.5). The score on the Modified Fatigue Impact Scale (MFIS pathological if score ¿35) was noted for each patient.ResultsOf the 176 patients included: 22.3% were NAb positive, 54.5% presented non-response criteria to IFNß, and 57.4% had a pathological MFIS score. Fatigue was increased in NAb¿+¿patients (p¿=¿0.0014) and they were more likely to present non-response criteria to IFNß (p¿=¿0.041) than NAb- patients. Multivariate logistic regression analysis showed that the presence of NAb was related to fatigue (p¿=¿0.0032) and denoted disease activity in these patients (p¿=¿0.026).ConclusionsThis study demonstrates the impact of NAb on the non-clinical response to IFNß. Fatigue assessment is an indicator of IFNß responsiveness and a predictive biomarker of deterioration on patient¿s neurological status.
Complete list of metadatas

Cited literature [40 references]  Display  Hide  Download
Contributor : Christine Dupuis <>
Submitted on : Tuesday, January 20, 2015 - 11:02:26 AM
Last modification on : Sunday, October 25, 2020 - 7:07:00 AM
Long-term archiving on: : Friday, September 11, 2015 - 7:42:30 AM


Manceau et al. BMC Neurology 2...
Publisher files allowed on an open archive



Philippe Manceau, Clotilde Latarche, Sophie Pittion, Gilles Edan, Jérôme de Sèze, et al.. Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis.. BMC Neurology, BioMed Central, 2014, 14 (1), pp.215. ⟨10.1186/s12883-014-0215-y⟩. ⟨inserm-01103114v2⟩



Record views


Files downloads